To include your compound in the COVID-19 Resource Center, submit it here.

EPI-743: Phase IIb/III started

Edison and Dainippon began a 6-month, open-label, Japanese Phase IIb/III trial to evaluate EPI-743 in >=5 children with

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE